Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Kd2mdj4gab
2. 2417135-66-9
3. N-(4-(2-methoxy-3-(1-(trideuteriomethyl)-1,2,4-triazol-3-yl)anilino)-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl)cyclopropanecarboxamide
4. N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl]cyclopropanecarboxamide
5. Refchem:1084119
6. Envudeucitinibum
7. Envudeucitinib [inn]
8. Envudeucitinib (usan/inn)
9. Envudeucitinib [usan]
10. Chembl5415395
11. Schembl30697049
12. Gtpl13205
13. Esk-001
14. Ftp-637
15. Yqf2513
16. Bdbm756380
17. Ex-a15179
18. Us12351572, Example 195
19. Hy-153701s
20. D13123
21. Cyclopropanecarboxamide, N-[4-[[2-methoxy-3-[1-(methyl-d3)-1h-1,2,4-triazol-3-yl]phenyl]amino]-5-(1-oxopropyl-3,3,3-d3)-2-pyridinyl]-
22. N-(4-((2-methoxy-3-(1-(methyl-d3)-1h-1,2,4-triazol-3-yl)phenyl)amino)-5-(propanoyl-3,3,3-d3)pyridin-2-yl)cyclopropanecarboxamide
23. N-[4-[[2-methoxy-3-[1-(methyl-d3)-1h-1,2,4-triazol-3-yl]phenyl]amino]-5-(1-oxopropyl-3,3,3-d3)-2-pyridinyl]cyclopropanecarboxamide
| Molecular Weight | 426.5 g/mol |
|---|---|
| Molecular Formula | C22H24N6O3 |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 111 |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 645 |
| Isotope Atom Count | 6 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
96
PharmaCompass offers a list of Envudeucitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Envudeucitinib manufacturer or Envudeucitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Envudeucitinib manufacturer or Envudeucitinib supplier.
A Envudeucitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Envudeucitinib, including repackagers and relabelers. The FDA regulates Envudeucitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Envudeucitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Envudeucitinib supplier is an individual or a company that provides Envudeucitinib active pharmaceutical ingredient (API) or Envudeucitinib finished formulations upon request. The Envudeucitinib suppliers may include Envudeucitinib API manufacturers, exporters, distributors and traders.
Envudeucitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Envudeucitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Envudeucitinib GMP manufacturer or Envudeucitinib GMP API supplier for your needs.
A Envudeucitinib CoA (Certificate of Analysis) is a formal document that attests to Envudeucitinib's compliance with Envudeucitinib specifications and serves as a tool for batch-level quality control.
Envudeucitinib CoA mostly includes findings from lab analyses of a specific batch. For each Envudeucitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Envudeucitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Envudeucitinib EP), Envudeucitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Envudeucitinib USP).
